Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.41 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.41 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.41 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.38 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.38 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30437086 | 1.00 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| Water SCHEMBL22491700 | 1.00 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| SCHEMBL21048281 | 0.99 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| SCHEMBL20480080 | 0.78 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL30436776 | 0.78 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL20482712 | 0.78 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL22491774 | 0.76 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL30436956 | 0.76 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL22466776 | 0.76 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL22491683 | 0.75 | ADRA2A (0.45) | TSHRDRD4ADRA1BADRA2AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630049-B | Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof | 奥赖恩公司 | 2023-06-20 | — | — | CN | claimed |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ORION CORPORATION (FI) | 2022-06-07 | — | — | US | claimed |
| EP-3717476-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | Orion Corporation (FI) | 2020-10-07 | — | — | EP | claimed |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2020-10-01 | — | — | US | claimed |
| CN-111630049-A | Process for the preparation of 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and its bisulphate | 奥赖恩公司 | 2020-09-04 | — | — | CN | claimed |
| CN-111630049-B | Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof | 奥赖恩公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111630049-B | Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof | 奥赖恩公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ORION CORPORATION (FI) | 2022-06-07 | — | — | US | disclosed |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ORION CORPORATION (FI) | 2022-06-07 | — | — | US | disclosed |
| EP-3717476-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | Orion Corporation (FI) | 2020-10-07 | — | — | EP | disclosed |
| EP-3717476-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | Orion Corporation (FI) | 2020-10-07 | — | — | EP | disclosed |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2020-10-01 | — | — | US | disclosed |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2020-10-01 | — | — | US | disclosed |
| CN-111630049-A | Process for the preparation of 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and its bisulphate | 奥赖恩公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111630049-A | Process for the preparation of 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and its bisulphate | 奥赖恩公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019106238-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2019-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ADRA2A, ADRA2C, ADRB2 | DRD4 922/4885ADRA1B 12/4885ADRA2A 1/4885 |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ADRA2A, ADRA2C, ADRB2 | DRD4 808/4885ADRA1B 10/4885ADRA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.